CHF Solutions, Inc. to Present Healthcare Cost Analysis of Aquadex FlexFlow System Compared to Standard of Care in Heart Failure Patients with Fluid Overload at ISPOR Conference

EDEN PRAIRIE, Minn., April 26, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS) announces today that new comparative data between the company’s Aquadex FlexFlow system and pharmaceutical therapy will be presented in a poster session at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference.

The poster, titled “Ultrafiltration vs. Diuretics for the Treatment of Fluid Overload in Heart Failure Patients: A Hospital Cost Analysis,” will be presented on Wednesday, May 23, 2018 at the Baltimore Convention Center, Baltimore, Md.

“We have long established the viability of ultrafiltration therapy through both robust clinical evidence and customer experience,” said John Erb, chairman and chief executive officer of CHF Solutions.  "We are pleased to be presenting these data at the ISPOR conference, which will provide additional evidence for physicians to consider when choosing a therapy for fluid overloaded heart failure patients.” About CHF Solutions

CHF Solutions, Inc. (NASDAQ: CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.

CONTACTS:

INVESTORS: Claudia Napal Drayton Chief Financial Officer CHF Solutions, Inc. 952-345-4205 [email protected]

-or- Bret Shapiro Managing Partner CORE IR 516-222-2560 [email protected] www.coreir.com

MEDIA Jules Abraham JQA Partners, Inc. 917-885-7378 [email protected]

You May Also Be Interested In

• Redo Announces $81 Million Series B to Support Commerce Technology Expansion
• Tutor Perini Prices $400 Million of Senior Notes Due 2033
• Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility